Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Mok, Tony
Wu, Yi-Long
Watson, Patricia A.
Zhang, Jin
Rangwala, Reshma A.
Lopes, Gilberto
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Soc Clin Oncol, Guangzhou, Guangdong, Peoples R China
[3] IASLC, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[5] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Ctr Paulista Oncol & HCor Onco, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8105
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
    Gandhi, Leena
    Balmanoukian, Ani
    Hui, Rina
    Hamid, Omid
    Rizvi, Naiyer A.
    Leighl, Natasha
    Gubens, Matthew
    Goldman, Jonathan W.
    Lubiniecki, Gregory M.
    Emancipator, Kenneth
    Dolled-Filhart, Marisa
    Lunceford, Jared K.
    Niewood, Michelle
    Gergich, Kevin
    Garon, Edward B.
    CANCER RESEARCH, 2014, 74 (19)
  • [42] THE PROMISING ROLE OF PEMBROLIZUMAB IN THE MANAGEMENT OF PATIENTS WITH PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
    Gadi, H. R.
    Gollala, M. K.
    Kethireddy, K.
    Ganta, M. R.
    Kankanampati, N.
    VALUE IN HEALTH, 2018, 21 : S17 - S17
  • [43] Disease-driven symptoms and response to chemotherapy in treatment-naive patients with advanced non-small cell lung cancer (NSCLC).
    Jones, Desiree
    Vichaya, Elisabeth G.
    Wang, Xin Shelley
    Mendoza, Tito R.
    Mobley, Gary M.
    Lu, Charles
    Cleeland, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
    Lu, S.
    Fang, J.
    Liu, A.
    Dong, X.
    Yu, Y.
    Han, S.
    Zeng, Z.
    Zhang, R.
    Lu, P.
    Shi, H.
    Tan, P.
    Fan, S.
    Shi, M.
    Su, W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1656 - S1656
  • [45] Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA
    Huang, Min
    Lopes, Gilberto de Lima
    Insinga, Ralph P.
    Burke, Thomas
    Ejzykowicz, Flavia
    Zhang, Ying
    Feliciano, Josephine L.
    IMMUNOTHERAPY, 2019, 11 (17) : 1463 - 1478
  • [46] Safety and efficacy of pembrolizumab (Pembro) monotherapy in elderly patients (Pts) with PD-L1-positive advanced NSCLC: Pooled analysis from KEYNOTE-010,-024, and-042
    Nosaki, K.
    Hosomi, Y.
    Saka, H.
    Baas, P.
    de Castro, G., Jr.
    Reck, M.
    Wu, Y-L.
    Brahmer, J. R.
    Felip, E.
    Sawada, T.
    Noguchi, K.
    Han, S. R.
    Piperdi, B.
    Kush, D. A.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 39 - 39
  • [47] Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
    Felip, E.
    Martini, J-F.
    Mazieres, J.
    Kim, D-W.
    Shepard, D.
    Polli, A.
    Liu, G.
    de Marinis, F.
    Toffalorio, F.
    Goto, Y.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1014 - S1014
  • [48] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
    Wainberg, Zev A.
    Shitara, Kohei
    Van Cutsem, Eric
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol Cheol
    Lee, Jeeyun
    Castro-Salguero, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Goekkurt, Eray
    Satake, Hironaga
    Chao, Joseph
    Kher, Uma
    Shah, Sukrut
    Bhagia, Pooja
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [49] A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer
    Herbst, Roy S.
    Gurpide, Alfonso
    Surmont, Veerle
    Kim, Dong-Wan
    Waqar, Salem Naheed
    Herder, Judith
    Lee, Dae Ho
    Carcereny, Enric
    Reguart, Naomi
    Wallmark, John M.
    Ramalingam, Suresh S.
    Langer, Corey J.
    Lubiniecki, Gregory M.
    Knowles, James
    Zhou, Honghong
    Hanson, Mary Elizabeth
    Baas, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
    Mienko, Fiona
    Halmos, Balazs
    Cheng, Haiying
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
12345